CA
CRDF icon

Cliff Asness’s Cardiff Oncology CRDF Stock Holding History

Cliff Asness’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$450K Buy
346,353
+280,197
+424% +$445K ﹤0.01% 3436
2026
Q1 		$107K Buy
+66,156
New +$136K ﹤0.01% 3680
2025
Q4 		– Sell
-48,281
Closed -$99.5K – 3584
2025
Q3 		$99.5K Buy
48,281
+29,360
+155% +$81.1K ﹤0.01% 3370
2025
Q2 		$59.6K Sell
18,921
-10,262
-35% -$31.3K ﹤0.01% 3229
2025
Q1 		$91.6K Sell
29,183
-11,456
-28% -$45.3K ﹤0.01% 3025
2024
Q4 		$176K Buy
40,639
+9,770
+32% +$30.5K ﹤0.01% 2696
2024
Q3 		$82.4K Buy
+30,869
New +$72.9K ﹤0.01% 2670
2022
Q3 		– Sell
-54,580
Closed -$120K – 2219
2022
Q2 		$120K Sell
54,580
-308,703
-85% -$517K ﹤0.01% 2066
2022
Q1 		$901K Buy
363,283
+330,006
+992% +$1.17M ﹤0.01% 1594
2021
Q4 		$200K Sell
33,277
-2,776
-8% -$16.5K ﹤0.01% 2088
2021
Q3 		$240K Buy
+36,053
New +$226K ﹤0.01% 2103

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Cliff Asness's CRDF Position: Q2 2026 in Review

Cliff Asness increased its Cardiff Oncology (CRDF) stake by 424% in Q2 2026, buying an estimated $445K and bringing the position to 346,353 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #3436.

Cliff Asness first reported a position in CRDF in Q3 2021 and has held it in 11 quarters since. The position peaked at $901K in Q1 2022. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Cliff Asness held 346,353 shares of Cardiff Oncology worth $450K as of Q2 2026.
  • Cliff Asness bought 280,197 Cardiff Oncology shares in Q2 2026, an estimated $445K.
  • Cardiff Oncology made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3436 holding.
  • Cliff Asness first reported a position in Cardiff Oncology in Q3 2021 and has held it in 11 quarters since.
  • Cliff Asness's Cardiff Oncology position peaked at $901K in Q1 2022.
  • 104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.